Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Ryota Dokuni"'
Autor:
Kiyoko Fukuda, Naoko Katsurada, Yoshitaka Kawa, Miyako Satouchi, Kazumi Kaneshiro, Masataka Matsumoto, Rei Takamiya, Yukihisa Hatakeyama, Ryota Dokuni, Kanoko Matsumura, Masahiro Katsurada, Kyosuke Nakata, Sho Yoshimura, Motoko Tachihara
Publikováno v:
Heliyon, Vol 9, Iss 10, Pp e20463- (2023)
Objectives: The combination of chemotherapy and immune checkpoint inhibitors (chemo-ICI) has become the new standard of treatment for extensive-stage small cell lung cancer (ES-SCLC). Recently, slight changes in interstitial shadows, defined as inter
Externí odkaz:
https://doaj.org/article/20aacf7af09f46aab70f39873294bfe3
Autor:
Chihiro Mimura, Kazumi Kaneshiro, Shodai Fujimoto, Ryota Dokuni, Natsuhiko Iwamoto, Kanoko Matsumura, Yukihisa Hatakeyama, Yuko Kono, Motoko Tachihara
Publikováno v:
Thoracic Cancer, Vol 14, Iss 6, Pp 584-591 (2023)
Abstract Background Osimertinib is associated with a relatively high frequency of drug‐induced interstitial lung disease (D‐ILD), and transient asymptomatic pulmonary opacities (TAPO) have been reported to occur during osimertinib administration.
Externí odkaz:
https://doaj.org/article/08f25ea72cab40159dd7263d20e634f6
Autor:
Naoko Katsurada, Tatsuya Nagano, Masatsugu Yamamoto, Tatsunori Kiriu, Ryota Dokuni, Hiroshi Kamiryo, Ai Yoshioka, Atsushi Fukunaga, Chikako Nishigori, Yoshihiro Nishimura, Kazuyuki Kobayashi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-6 (2022)
Abstract Cholinergic urticaria (CholU) is classified into several subtypes: (1) conventional sweat allergy-type CholU (conventional SAT-CholU), (2) CholU with palpebral angioedema (CholU-PA), 3) CholU with acquired anhidrosis and/or hypohidrosis (Cho
Externí odkaz:
https://doaj.org/article/f6b1f0ffbef44a4b99e19c3a4638f9ae
Autor:
Ryota Dokuni, Tatsuya Nagano, Naoe Jimbo, Hiroki Sato, Tatsunori Kiriu, Yuichiro Yasuda, Masatsugu Yamamoto, Motoko Tachihara, Kazuyuki Kobayashi, Yoshimasa Maniwa, Yoshihiro Nishimura
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-8 (2020)
Abstract Background Recent studies have revealed that serpin peptidase inhibitor clade E member 2 (SERPINE2) is associated with tumorigenesis. However, SERPINE2 expression and its role in lung adenocarcinomas are still unknown. Methods The expression
Externí odkaz:
https://doaj.org/article/023f2403f18b4c3e98a301f1f1982837
Autor:
Motoko Tachihara, Ryota Dokuni, Keiko Okuno, Shuntaro Tokunaga, Kyosuke Nakata, Naoko Katsurada, Masatsugu Yamamoto, Tatsuya Nagano, Kazuyuki Kobayashi, Yugo Tanaka, Yasuhiro Funada, Yoshimasa Maniwa, Yoshihiro Nishimura
Publikováno v:
Thoracic Cancer, Vol 11, Iss 9, Pp 2536-2541 (2020)
Background Cisplatin (CDDP) and vinorelbine as an adjuvant chemotherapy improve the overall survival of patients with completely resected non‐small cell lung cancer (NSCLC). However, the treatment completion rate is low due to severe adverse events
Externí odkaz:
https://doaj.org/article/e26a710639fb4bffb215797509ffae2d
Autor:
Kanoko Umezawa, Tatsuya Nagano, Kazuyuki Kobayashi, Ryota Dokuni, Masahiro Katsurada, Masatsugu Yamamoto, Yoko Yoshikawa, Tohru Kataoka, Yoshihiro Nishimura
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-12 (2019)
Abstract Background We have shown that phospholipase Cε (PLCε), an effector of Ras and Rap1 small GTPases, plays pivotal roles in inflammation and inflammation-associated carcinogenesis by augmenting proinflammatory cytokine production from epithel
Externí odkaz:
https://doaj.org/article/f038243915e8423fb75813a763b7a949
Autor:
Yoshitaka Kawa, Tatsuya Nagano, Asuka Yoshizaki, Ryota Dokuni, Masahiro Katsurada, Tomomi Terashita, Yuichiro Yasuda, Kanoko Umezawa, Masatsugu Yamamoto, Hiroshi Kamiryo, Kazuyuki Kobayashi, Yoshihiro Nishimura
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0203211 (2018)
BACKGROUND:Sphingosine kinase phosphorylates sphingosine to generate sphingosine 1 phosphate (S1P) following stimulation of the five plasma membrane G-protein-coupled receptors. The objective of this study is to clarify the role of S1P and its recept
Externí odkaz:
https://doaj.org/article/e0d1dae90778448ba779d789f2b5796c
Autor:
Ryosuke Kamimura, Hidehito Matsuoka, Yukio Kashima, Ryota Dokuni, Tatsunori Kiriu, Keiko Okuno, Yoshikazu Kotani
Publikováno v:
Haigan. 62:406-410
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d159ad62a5fc997661e99fdf38aa9016
https://doi.org/10.2482/haigan.62.406
https://doi.org/10.2482/haigan.62.406
Autor:
Ryosuke Kamimura, Hidehito Matsuoka, Yukio Kashima, Ryota Dokuni, Tatsunori Kiriu, Keiko Okuno, Yoshikazu Kotani
Publikováno v:
Haigan. 62:97-102
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d6ced40bb9fccab091c40f853c94e9e
https://doi.org/10.2482/haigan.62.97
https://doi.org/10.2482/haigan.62.97
Autor:
Chihiro Mimura, Kazumi Kaneshiro, Shodai Fujimoto, Ryota Dokuni, Natsuhiko Iwamoto, Kanoko Matsumura, Yukihisa Hatakeyama, Yuko Kono, Motoko Tachihara
Publikováno v:
Thoracic cancerREFERENCES.
Background Osimertinib is associated with a relatively high frequency of drug-induced interstitial lung disease (D-ILD), and transient asymptomatic pulmonary opacities (TAPO) have been reported to occur during osimertinib administration. The frequenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2830c50bdd9b072e8fc33d86a7d5b6e2
https://pubmed.ncbi.nlm.nih.gov/36578073
https://pubmed.ncbi.nlm.nih.gov/36578073